相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1974
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- A new decision-analytic modeling study published in Blood finds NMAC-HID allo-HSCT delivers the best clinical value among curative sickle cell treatments. - Gene therapy accrued the highest QALYs (22.1) at $2.75 million, while stem cell transplant achieved 20.1 QALYs at $1.15 million, and standard care yielded 14.3 QALYs at $1.22 million. - Researchers determined gene therapy would need a 66% to 71% price reduction — to $627,000–$740,000 — to be cost-competitive with stem cell transplantation in the United States. - Lead author Dr. George Goshua emphasized that cost-effectiveness data should inform policy, not limit patient access, and that shared decision-making remains essential.
- Sacituzumab govetecan, an FDA-approved breast cancer drug, demonstrated significant activity in treatment-resistant uterine cancer, shrinking tumors by 30% or more in 28% of patients in a Phase II trial. - The antibody-drug conjugate targets Trop-2 protein on cancer cells, delivering chemotherapy directly to tumor sites while sparing healthy tissue from widespread toxicity. - Over 70% of the 50 enrolled patients experienced some degree of tumor shrinkage, representing one of the most effective third-line treatments for uterine cancer to date. - The promising results have prompted initiation of a Phase III trial comparing the drug to standard chemotherapy in a larger patient population.
- Memorial Sloan Kettering Cancer Center is collaborating with Triomics to deploy an AI-powered clinical trial matching platform that reduces patient screening time from 45 minutes to near real-time processing. - Yale Cancer Center and Smilow Cancer Hospital will expand Triomics' AI screening system across their entire portfolio of over 400 active oncology clinical trials. - The platform automatically analyzes patient records and provides ranked trial matches with detailed rationale and source citations, enabling research teams to identify more eligible patients efficiently. - Triomics' technology has demonstrated expert-level accuracy in clinical trial screening as published in Nature Digital Medicine, transforming manual chart review into streamlined automated processes.
- Yale researchers have developed a novel mRNA vaccine that targets both the viral large T antigen protein essential for tumor growth and incorporates interleukin-7 to enhance immune responses against Merkel cell carcinoma. - The dual-action vaccine demonstrated potent anti-tumor effects in both animal models and patient samples, with improved effectiveness when IL-7 was added to strengthen T cell responses and memory formation. - The vaccine showed promising synergy with anti-PD-1 immunotherapy in animal studies, suggesting potential applications across multiple treatment scenarios including surgical adjuvant therapy and combination treatments for metastatic disease. - Researchers are currently conducting investigational new drug enabling studies and seeking partners to advance the vaccine toward clinical trials for this rare but aggressive skin cancer.
- BriaCell Therapeutics has been awarded a $2,054,651 non-dilutive grant from the National Cancer Institute to advance Bria-PROS+, a next-generation personalized off-the-shelf immunotherapy for prostate cancer. - The grant will fund manufacturing of clinical supplies and support a Phase 1/2a trial in patients with metastatic prostate cancer, led by Dr. William Oh at Yale Cancer Center. - The Bria-OTS+ platform is designed to overcome the complexity, cost, and delays of traditional personalized cancer treatments while addressing the urgent unmet medical need in advanced prostate cancer. - Despite recent advances in metastatic hormone-sensitive prostate cancer management, most patients still progress with significant pain and limited treatment options.
- New clinical guidelines for peritoneal surface malignancies have been published for the first time since 2018, addressing care disparities for approximately 70,000-80,000 US patients affected annually. - The updated guidelines feature enhanced representation including patient advocates, international stakeholders, and endorsement from the Society of Surgical Oncology, with adoption into NCCN guidelines. - The guidelines aim to address critical challenges including difficult imaging detection, exclusion from clinical trials, and advanced disease presentation that often leads to bowel obstructions and poor outcomes. - A methodologically rigorous Delphian process was used to create seven comprehensive papers covering different treatment pathways, published jointly in Cancer and Annals of Surgical Oncology.
- Chromophobe renal cell carcinoma (ChRCC) demonstrates an immune-cold tumor microenvironment with significantly reduced CD8+ T-cell infiltration compared to clear cell RCC, explaining poor immunotherapy responses. - Patients with metastatic chromophobe RCC receiving immune checkpoint inhibitor-based therapies achieved inferior survival outcomes with median overall survival of 24.7 months versus 50.5 months in clear cell RCC patients. - The study identified α-intercalated cells as the cellular origin of chromophobe RCC and revealed potential therapeutic targets including ferroptosis pathways and mTOR signaling. - Real-world analysis showed mTOR inhibitors may offer superior outcomes in chromophobe RCC compared to immunotherapy, with median overall survival of 41.3 months versus 13.4 months in clear cell RCC patients.
- BostonGene and SWOG Cancer Research Network launched the PRISM study, a randomized Phase II trial evaluating biomarker-directed therapy for extensive stage small cell lung cancer patients. - The NCI-supported trial will enroll up to 900 patients and use BostonGene's AI-powered multiomics platform to identify molecular subtypes and assign personalized treatments. - Current standard treatment extends overall survival by only 2-3 months, with most patients experiencing disease progression despite combination chemotherapy and immunotherapy. - The study builds on previous SWOG S1929 trial findings that demonstrated promising improvements in progression-free survival using targeted approaches based on four distinct SCLC molecular subtypes.
- The UNC Lineberger Comprehensive Cancer Center received $28 million from ARPA-H to develop EVOLVE, an innovative clinical trial that adapts metastatic breast cancer treatment in real-time based on tumor changes. - The trial will enroll up to 700 patients and use biomarkers, including circulating tumor DNA, to detect treatment resistance early and modify therapy before symptoms return. - EVOLVE represents a paradigm shift from traditional clinical trials by continuously monitoring tumor evolution and matching patients to the most promising therapies as their cancer changes. - The collaborative effort involves 15 institutions across the Translational Breast Cancer Research Consortium, addressing the critical need for curative therapies in metastatic breast cancer where only one in three patients survive beyond five years.
- A machine learning-based approach integrating tumor and circulating biomarkers demonstrated superior predictive capability compared to individual biomarkers alone for patients with advanced renal cell carcinoma treated with nivolumab plus cabozantinib. - The multivariate model identified 10 predictive features across four biomarker categories, showing substantially improved outcome prediction compared to univariate analysis of six features with modest predictive ability. - Researchers analyzed over 4,000 measurements across 150 patients from the CheckMate 9ER trial, identifying circulating extracellular matrix proteins as novel biomarkers associated with treatment outcomes. - The findings provide a foundation for future integrative biomarker discovery in kidney cancer, addressing the current challenge that determinants of response and resistance to checkpoint inhibitors remain largely unknown.
